Home ▻ Research▻People▻Medicine

Medicine

Dr Linda Howard

B.Sc., Ph.D.

 
researcher
 

Biography

Linda Howard is  a lecturer in cellular therapies at the Regenerative Medicine Institute (REMEDI) at NUI Galway.
Linda graduated from the University of Warwick, Coventry UK with a degree in Microbiology and Microbial Technology. She completed a Ph.D. with the Medical Research Council (MRC) Toxicology Unit in the UK on cloning and characterising a novel proteolytic enzyme. Based on her interest in proteolytic enzymes she moved to the laboratory of Professor Wen-Tien Chen as a Post-doctoral Research Fellow in the Lombardi Cancer Center at Georgetown University, Washington DC, USA  where she conducted research on the role of proteolytic enzymes in tumour cell invasion and metastasis. Following this she undertook a Post-doctoral Research Fellowship with Professor Blobel at Memorial Sloan Kettering Cancer Center, New York, NY, USA where she worked on cloning, characterising and analysing the function of cell surface proteolytic enzymes.
Following her postdoctoral work Linda worked for 4 years as a Scientist at Osiris Therapeutics in Baltimore MD USA. This company was developing therapies based on adult stem cells and obtained the first approval of an ex vivo expanded stem cell therapy.
Linda moved from the USA to REMEDI at NUI Galway to participate in the development of a stem cell research program  In 2007 Linda started the M.Sc. in Regenerative Medicine which she now directs. To date nearly 300 students have graduated from this course and have gone onto careers all over the world.
Her research interests include:
- Stem cell biology, in particular regulation of stem cell differentiation; stem cell deficits associated with disease and aging; genetic modification to enhance stem cell function and to study stem cell biology.
-Development of release assays and preclinical assays of biodistribution in support of clinical trials and translation of cell and gene therapies to the clinic.
-Gene therapy (using RNA interference and lentiviral systems) to modify gene expression to enhance regeneration after spinal cord injury and to reduce the production of the glial scar.
-Biomaterial scaffolds for delivery of cells or viral vectors to the central nervous system. 

Research Interests

Adult stem cells, Regulation of Stem Cell Differentiation, micro RNA regulation of cell proliferation and differentiation, Gene Therapy, RNA interference, Lentiviral vectors, Spinal Cord Injury, Glial Scar, Biomaterials.

Research Projects

  Project Start Date End Date
Lentiviral vector-mediated modification of the injured spinal cord using a hydrogel delivery system to enhance repair and regeneration. 01-AUG-24 31-JUL-28

Peer Reviewed Journals

  Year Publication
(2022) 'Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with no-option critical limb ischemia; observations on feasibility of the autologous approach from a clinical trial'
Mohamed SA, Duffy A, McInerney V, Krawczyk J, Hayat A, Naughton S, Finnerty A, Holohan M, Liew A, Tubassam M, Walsh SR, O'Brien T, Howard L (2022) 'Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with no-option critical limb ischemia; observations on feasibility of the autologous approach from a clinical trial'. Cytotherapy, 24 (12):1259-1267 [DOI] [Details]
(2008) 'Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis'
Sharif F, Hynes SO, Cooney R, Howard L, McMahon J, Daly K, Crowley J, Barry F, O'Brien T. (2008) 'Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis'. Molecular Therapy, [Details]
(2007) 'Effect of gene delivery of NOS isoforms on intimal hyperplasia and endothelial regeneration after balloon injury'
Cooney R, Hynes SO, Sharif F, Howard L, O'Brien T. (2007) 'Effect of gene delivery of NOS isoforms on intimal hyperplasia and endothelial regeneration after balloon injury'. Gene Therapy, [Details]
(2019) 'Long QT Syndrome: Genetics and Future Perspective'
Wallace, E., Howard, L., Liu, M., O¿Brien, T., Ward, D., Shen, S., & Prendiville, T. (2019) 'Long QT Syndrome: Genetics and Future Perspective'. Pediatric Cardiology, 1957 :1419-1430 [DOI] [Details]
(2023) 'Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson's and Alzheimer's Disease'
Keighron CN, Avazzadeh S, Goljanek-Whysall K, McDonagh B, Howard L, Ritter T, Quinlan LR (2023) 'Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson's and Alzheimer's Disease'. Biomedicines, 11 (3) [DOI] [Details]
(2019) 'TNF-¿/IL-1ß-licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell-mediated induction of Foxp3 + regulatory T cells in the lung'
Murphy N, Treacy O, Lynch K, Morcos M, Lohan P, Howard L, Fahy G, Griffin MD, Ryan AE, Ritter T. (2019) 'TNF-¿/IL-1ß-licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell-mediated induction of Foxp3 + regulatory T cells in the lung'. Faseb J, [Details]
(2021) 'Lentiviral Vectors Delivered with Biomaterials as Therapeutics for Spinal Cord Injury'
Shortiss, C; Howard, L; McMahon S (2021) 'Lentiviral Vectors Delivered with Biomaterials as Therapeutics for Spinal Cord Injury'. Cells, [DOI] [Details]
(2021) 'Validation of ERICVA Risk Score as a Predictor of One Year Amputation-Free Survival of Patients with Critical Limb Ischemia'
Mohamed SA;Viknaswaran NL;Doran J;Sanz-Nogués C;Ahmed K;Howard L;Tubassam M;O'Brien T;Walsh SR; (2021) 'Validation of ERICVA Risk Score as a Predictor of One Year Amputation-Free Survival of Patients with Critical Limb Ischemia'. Annals Of Vascular Surgery, [DOI] [Details]
(2021) 'Derivation of four iPSC lines from a male ASD patient carrying a deletion in the middle coding region of NRXN1¿ gene (NUIGi039-A and NUIGi039-B) and a male sibling control (NUIGi040-A and NUIGi040-B)'
Ding Y;O'Brien A;Marcó de la Cruz B;Yang M;Lu Y;Qian X;Yang G;McInerney V;Krawczyk J;Lynch SA;Howard L;Allen NM;O'Brien T;Gallagher L;Shen S; (2021) 'Derivation of four iPSC lines from a male ASD patient carrying a deletion in the middle coding region of NRXN1¿ gene (NUIGi039-A and NUIGi039-B) and a male sibling control (NUIGi040-A and NUIGi040-B)'. Stem Cell Research, 53 [DOI] [Details]
(2021) 'Derivation of iPSC lines from two patients with autism spectrum disorder carrying NRXN1¿ deletion (NUIGi041-A, NUIG041-B; NUIGi045-A) and one sibling control (NUIGi042-A, NUIGi042-B)'
Ding Y;O'Brien A;de la Cruz BM;Yang M;Fitzgerald J;Yang G;Li W;McInerney V;Krawczyk J;Lynch SA;Howard L;Allen NM;O'Brien T;Gallagher L;Shen S; (2021) 'Derivation of iPSC lines from two patients with autism spectrum disorder carrying NRXN1¿ deletion (NUIGi041-A, NUIG041-B; NUIGi045-A) and one sibling control (NUIGi042-A, NUIGi042-B)'. Stem Cell Research, 52 [DOI] [Details]
(2020) 'Ex Vivo Rat Transected Spinal Cord Slices as a Model to Assess Lentiviral Vector Delivery of Neurotrophin-3 and Short Hairpin RNA against NG2'
Patar A;Dockery P;McMahon S;Howard L; (2020) 'Ex Vivo Rat Transected Spinal Cord Slices as a Model to Assess Lentiviral Vector Delivery of Neurotrophin-3 and Short Hairpin RNA against NG2'. Biology, 9 (3) [DOI] [Details]
(2020) 'Derivation of familial iPSC lines from three patients with retinitis pigmentosa carrying an autosomal dominant RPE65 mutation (NUIGi027-A, NUIGi028-A, NUIGi029-A)'
Ding Y;Carvalho E;Murphy C;McInerney V;Krawczyk J;O'Brien T;Howard L;Cai L;Shen S; (2020) 'Derivation of familial iPSC lines from three patients with retinitis pigmentosa carrying an autosomal dominant RPE65 mutation (NUIGi027-A, NUIGi028-A, NUIGi029-A)'. Stem Cell Research, 43 [DOI] [Details]
(2020) 'Derivation of two iPSC lines from a sporadic ASD patient (NUIGi033-A) and a paternal control (NUIGi034-A)'
de la Cruz BM;Ding Y;McInerney V;Krawczyk J;Lu Y;Yang G;Qian X;Li W;Howard L;Allen NM;O'Brien T;Gallagher L;Shen S; (2020) 'Derivation of two iPSC lines from a sporadic ASD patient (NUIGi033-A) and a paternal control (NUIGi034-A)'. Stem Cell Research, 44 [DOI] [Details]
(2020) 'Autologous bone marrow mesenchymal stromal cell therapy for no-option critical limb ischemia is limited by karyotype abnormalities'
Mohamed SA;Howard L;McInerney V;Hayat A;Krawczyk J;Naughton S;Finnerty A;Holohan M;Duffy A;Moloney T;Kavanagh E;Burke P;Liew A;Tubassam M;Walsh SR;O'Brien T; (2020) 'Autologous bone marrow mesenchymal stromal cell therapy for no-option critical limb ischemia is limited by karyotype abnormalities'. Cytotherapy, [DOI] [Details]
(2019) 'Derivation of familial iPSC lines from three ASD patients carrying NRXN1¿+/- and two controls (NUIGi022-A, NUIGi022-B; NUIGi023-A, NUIGi023-B; NUIGi025-A, NUIGi025-B; NUIGi024-A, NUIGi024-B; NUIGi026-A, NUIGi026-B)'
Ding Y;Marcó de la Cruz B;Xia Y;Liu M;Lu Y;McInerney V;Krawczyk J;Lynch SA;Howard L;O'Brien T;Gallagher L;Shen S; (2019) 'Derivation of familial iPSC lines from three ASD patients carrying NRXN1¿+/- and two controls (NUIGi022-A, NUIGi022-B; NUIGi023-A, NUIGi023-B; NUIGi025-A, NUIGi025-B; NUIGi024-A, NUIGi024-B; NUIGi026-A, NUIGi026-B)'. Stem Cell Research, 41 [DOI] [Details]
(2019) 'Analysis of reactive astrocytes and NG2 proteoglycan in ex vivo rat models of spinal cord injury'
Patar, A,Dockery, P,Howard, L,McMahon, S (2019) 'Analysis of reactive astrocytes and NG2 proteoglycan in ex vivo rat models of spinal cord injury'. Journal Of Neuroscience Methods, 311 :418-425 [DOI] [ARAN Link] [Details]
(2019) 'TNF-a/IL-1ß-licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell-mediated induction of Foxp3+ regulatory T cells in the lung'
Murphy N;Treacy O;Lynch K;Morcos M;Lohan P;Howard L;Fahy G;Griffin MD;Ryan AE;Ritter T; (2019) 'TNF-a/IL-1ß-licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell-mediated induction of Foxp3+ regulatory T cells in the lung'. Faseb Journal, 33 :9404-9421 [DOI] [ARAN Link] [Details]
(2019) 'Survival/Adaptation of Bone Marrow-Derived Mesenchymal Stem Cells After Long-Term Starvation Through Selective Processes'
Ferro, F,Spelat, R,Shaw, G,Duffy, N,Islam, MN,O'Shea, PM,O'Toole, D,Howard, L,Murphy, JM (2019) 'Survival/Adaptation of Bone Marrow-Derived Mesenchymal Stem Cells After Long-Term Starvation Through Selective Processes'. Stem Cells, 37 :813-827 [DOI] [Details]
(2019) 'Cell viability in three ex vivo rat models of spinal cord injury'
Patar, A,Dockery, P,Howard, L,McMahon, SS (2019) 'Cell viability in three ex vivo rat models of spinal cord injury'. Journal Of Anatomy, 234 :244-251 [DOI] [ARAN Link] [Details]
(2017) 'Biodistribution and retention of locally administered human mesenchymal stromal cells: Quantitative polymerase chain reaction based detection of human DNA in murine organs'
Creane, M,Howard, L,O'Brien, T,Coleman, CM (2017) 'Biodistribution and retention of locally administered human mesenchymal stromal cells: Quantitative polymerase chain reaction based detection of human DNA in murine organs'. Cytotherapy, 19 :384-394 [DOI] [ARAN Link] [Details]
(2017) 'Circulating MicroRNAs in Cancer'
O'Brien, KP;Ramphul, E;Howard, L;Gallagher, WM;Malone, C;Kerin, MJ;Dwyer, RM (2017) 'Circulating MicroRNAs in Cancer'. Methods in Molecular Biology, 1509 :123-139 [DOI] [Details]
(2017) 'Circulating MicroRNAs in Cancer'
O'Brien, KP,Ramphul, E,Howard, L,Gallagher, WM,Malone, C,Kerin, MJ,Dwyer, RM,Rani, S (2017) 'Circulating MicroRNAs in Cancer'. Methods Mol Biol, 1509 :123-139 [DOI] [Details]
(2015) 'GDNF-SECRETING MESENCHYMAL STEM CELLS PROVIDE LOCALIZED NEUROPROTECTION IN AN INFLAMMATION-DRIVEN RAT MODEL OF PARKINSON'S DISEASE'
Hoban, DB,Howard, L,Dowd, E (2015) 'GDNF-SECRETING MESENCHYMAL STEM CELLS PROVIDE LOCALIZED NEUROPROTECTION IN AN INFLAMMATION-DRIVEN RAT MODEL OF PARKINSON'S DISEASE'. Neuroscience, 303 :402-411 [DOI] [Details]
(2015) 'Inefficiency in macromolecular transport of SCS-based microcapsules affects viability of primary human mesenchymal stem cells but not of immortalized cells'
Sanz-Nogués C;Horan J;Thompson K;Howard L;Ryan G;Kassem M;O'Brien T; (2015) 'Inefficiency in macromolecular transport of SCS-based microcapsules affects viability of primary human mesenchymal stem cells but not of immortalized cells'. Journal Of Biomedical Materials Research Part A, 103 (11) [DOI] [ARAN Link] [Details]
(2014) 'A chondromimetic microsphere for in situ spatially controlled chondrogenic differentiation of human mesenchymal stem cells'
Ansboro, S;Hayes, JS;Barron, V;Browne, S;Howard, L;Greiser, U;Lalor, P;Shannon, F;Barry, FP;Pandit, A;Murphy, JM (2014) 'A chondromimetic microsphere for in situ spatially controlled chondrogenic differentiation of human mesenchymal stem cells'. Journal Of Controlled Release, 179 :42-51 [DOI] [Details]
(2013) 'Growth differentiation factor-5 enhances in vitro mesenchymal stromal cell chondrogenesis and hypertrophy'
Coleman CM, Vaughan EE, Browe DC, Mooney E, Howard L, Barry F (2013) 'Growth differentiation factor-5 enhances in vitro mesenchymal stromal cell chondrogenesis and hypertrophy'. Stem Cells and Development, 22 (13):1968-1976 [DOI] [Details]
(2013) 'The reduction in immunogenicity of neurotrophin overexpressing stem cells after intra-striatal transplantation by encapsulation in an in situ gelling collagen hydrogel'
Hoban, DB,Newland, B,Moloney, TC,Howard, L,Pandit, A,Dowd, E (2013) 'The reduction in immunogenicity of neurotrophin overexpressing stem cells after intra-striatal transplantation by encapsulation in an in situ gelling collagen hydrogel'. Biomaterials, 34 :9420-9429 [DOI] [Details]
(2013) 'Allogeneic Murine Mesenchymal Stem Cells: Migration to Inflamed Joints In Vivo and Amelioration of Collagen Induced Arthritis When Transduced to Express CTLA4Ig'
Sullivan, C,Barry, F,Ritter, T,O'Flatharta, C,Howard, L,Shaw, G,Anegon, I,Murphy, M (2013) 'Allogeneic Murine Mesenchymal Stem Cells: Migration to Inflamed Joints In Vivo and Amelioration of Collagen Induced Arthritis When Transduced to Express CTLA4Ig'. Stem Cells And Development, 22 :3203-3213 [DOI] [Details]
(2012) 'Kinetics of thermally induced heat shock protein 27 and 70 expression by bone marrow-derived mesenchymal stem cells'
Moloney, TC;Hoban, DB;Barry, FP;Howard, L;Dowd, E (2012) 'Kinetics of thermally induced heat shock protein 27 and 70 expression by bone marrow-derived mesenchymal stem cells'. Protein Science, 21 :904-909 [DOI] [Details]
(2010) 'Survival and Immunogenicity of Mesenchymal Stem Cells From the Green Fluorescent Protein Transgenic Rat in the Adult Rat Brain'
Moloney, TC;Dockery, P;Windebank, AJ;Barry, FP;Howard, L;Dowd, E (2010) 'Survival and Immunogenicity of Mesenchymal Stem Cells From the Green Fluorescent Protein Transgenic Rat in the Adult Rat Brain'. Neurorehabilitation And Neural Repair, 24 :645-656 [DOI] [Details]
(2010) 'Potential of rat bone marrow-derived mesenchymal stem cells as vehicles for delivery of neurotrophins to the Parkinsonian rat brain'
Moloney, TC,Rooney, GE,Barry, FP,Howard, L,Dowd, E (2010) 'Potential of rat bone marrow-derived mesenchymal stem cells as vehicles for delivery of neurotrophins to the Parkinsonian rat brain'. Brain Research, 1359 :33-43 [DOI] [Details]
(2009) 'Neurotrophic Factor-Expressing Mesenchymal Stem Cells Survive Transplantation into the Contused Spinal Cord Without Differentiating into Neural Cells'
Rooney, GE,McMahon, SS,Ritter, T,Garcia, Y,Moran, C,Madigan, NN,Flugel, A,Dockery, P,O'Brien, T,Howard, L,Windebank, AJ,Barry, FP (2009) 'Neurotrophic Factor-Expressing Mesenchymal Stem Cells Survive Transplantation into the Contused Spinal Cord Without Differentiating into Neural Cells'. Tissue Engineering Part A, 15 :3049-3059 [DOI] [ARAN Link] [Details]
(2009) 'Elevation of cAMP in Mesenchymal Stem Cells Transiently Upregulates Neural Markers Rather than Inducing Neural Differentiation'
Rooney, GE,Howard, L,O'Brien, T,Windebank, AJ,Barry, FP (2009) 'Elevation of cAMP in Mesenchymal Stem Cells Transiently Upregulates Neural Markers Rather than Inducing Neural Differentiation'. Stem Cells And Development, 18 :387-398 [DOI] [Details]
(2008) 'Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model'
Mohr, A,Lyons, M,Deedigan, L,Harte, T,Shaw, G,Howard, L,Barry, F,O'Brien, T,Zwacka, R (2008) 'Mesenchymal stem cells expressing TRAIL lead to tumour growth inhibition in an experimental lung cancer model'. Journal Of Cellular And Molecular Medicine, 12 :2628-2643 [DOI] [Details]
(2008) 'Gene-eluting stents: Adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis'
Sharif, F;Hynes, SO;Cooney, R;Howard, L;McMahon, J;Daly, K;Crowley, J;Barry, F;O'Brien, T (2008) 'Gene-eluting stents: Adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis'. Molecular Therapy : The Journal Of The American Society Of Gene Therapy, 16 :1674-1680 [DOI] [Details]
(2008) 'Effects of plating density and culture time on bone marrow stromal cell characteristics'
Neuhuber B, Swanger SA, Howard L, Mackay A, Fischer I. (2008) 'Effects of plating density and culture time on bone marrow stromal cell characteristics'. Exp Hematol, 36 (9):1176-1185 [Details]
(2008) 'Gene-modified mesenchymal stem cells express functionally active nerve growth factor on an engineered poly lactic glycolic acid (PLGA) substrate'
Rooney, GE;Moran, C;McMahon, SS;Ritter, T;Maenz, M;Flugel, A;Dockery, P;O'Brien, T;Howard, L;Windebank, AJ;Barry, FP (2008) 'Gene-modified mesenchymal stem cells express functionally active nerve growth factor on an engineered poly lactic glycolic acid (PLGA) substrate'. Tissue Engineering Part A, 14 :681-690 [DOI] [Details]
(2007) 'Effect of gene delivery of NOS isoforms on intimal hyperplasia and endothelial regeneration after balloon injury'
Cooney, R;Hynes, SO;Sharif, F;Howard, L;O'Brien, T (2007) 'Effect of gene delivery of NOS isoforms on intimal hyperplasia and endothelial regeneration after balloon injury'. Gene Therapy, 14 :396-404 [DOI] [Details]
(2006) 'Gene transfer into rat mesenchymal stem cells: A comparative study of viral and nonviral vectors'
McMahon, JM;Conroy, S;Lyons, M;Greiser, U;O'Shea, C;Strappe, P;Howard, L;Murphy, M;Barry, F;O'Brien, T (2006) 'Gene transfer into rat mesenchymal stem cells: A comparative study of viral and nonviral vectors'. Stem Cells And Development, 15 :87-96 [Details]
(2004) 'Reevaluation of in vitro differentiation protocols for bone marrow stromal cells: disruption of actin cytoskeleton induces rapid morphological changes and mimics neuronal phenotype'
Neuhuber B, Gallo G, Howard L, Kostura L, Mackay A, Fischer I. (2004) 'Reevaluation of in vitro differentiation protocols for bone marrow stromal cells: disruption of actin cytoskeleton induces rapid morphological changes and mimics neuronal phenotype'. JOURNAL OF NEUROSCIENCE RESEARCH, 77 (2):192-204 [Details]
(2001) 'Catalytic activity of ADAM28'
Howard L, Zheng Y, Horrocks M, Maciewicz RA, Blobel C. (2001) 'Catalytic activity of ADAM28'. FEBS LETTERS, 498 (1):82-86 [Details]
(2000) 'Cloning and characterization of ADAM28: evidence for autocatalytic pro-domain removal and for cell surface localization of mature ADAM28'
Howard L, Maciewicz RA, Blobel CP. (2000) 'Cloning and characterization of ADAM28: evidence for autocatalytic pro-domain removal and for cell surface localization of mature ADAM28'. Biochem J, 348 (1):21-27 [Details]
(1999) 'Interaction of the metalloprotease disintegrins MDC9 and MDC15 with two SH3 domain-containing proteins, endophilin I and SH3PX1'
Howard L, Nelson KK, Maciewicz RA, Blobel CP. (1999) 'Interaction of the metalloprotease disintegrins MDC9 and MDC15 with two SH3 domain-containing proteins, endophilin I and SH3PX1'. J. BIOL. CHEM, 274 (44):31693-31699 [Details]
(1999) 'A novel protease-docking function of integrin at invadopodia'
Mueller SC, Ghersi G, Akiyama SK, Sang QX, Howard L, Pineiro-Sanchez M, Nakahara H, Yeh Y, Chen WT. (1999) 'A novel protease-docking function of integrin at invadopodia'. J. BIOL. CHEM, 274 (35):24947-24953 [Details]
(1997) 'Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease'
Piñeiro-Sánchez ML, Goldstein LA, Dodt J, Howard L, Yeh Y, Tran H, Argraves WS, Chen WT. (1997) 'Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease'. J. BIOL. CHEM, 272 (12):7595-7601 [Details]
(1997) 'Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion'
Nakahara H, Howard L, Thompson EW, Sato H, Seiki M, Yeh Y, Chen WT. (1997) 'Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion'. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, 94 (15):7959-7964 [Details]
(1996) 'Molecular cloning of MADM: a catalytically active mammalian disintegrin-metalloprotease expressed in various cell types'
Howard L, Lu X, Mitchell S, Griffiths S, Glynn P. (1996) 'Molecular cloning of MADM: a catalytically active mammalian disintegrin-metalloprotease expressed in various cell types'. Biochem J, 317 (1):45-50 [Details]
(1995) 'Membrane-associated metalloproteinase recognized by characteristic cleavage of myelin basic protein: assay and isolation'
Howard L, Glynn P. (1995) 'Membrane-associated metalloproteinase recognized by characteristic cleavage of myelin basic protein: assay and isolation'. Methods in Emzymology, 248 :388-395 [Details]

Conference Publications

  Year Publication
(2023) The European Orthopaedic Research Society (EORS) 31st Annual Meeting
Doyle, S.; Winrow, D.; Aregbesola, T.; Martin, J.; Pernevik, E.; Kuzmenko, V.; Howard, L.; Thompson, K.; Johnson, M.; Coleman, C. (2023) FABRICATION OF A HIGH-THROUGHPUT 3D-PRINTED OSTEOGENIC CORAL-CONTAINING SCAFFOLD The European Orthopaedic Research Society (EORS) 31st Annual Meeting Porto, Portugal, , 27-SEP-23 - 29-SEP-23 , pp.129-129 [DOI] [Details]
(2017) Sylvester O’Halloran Meeting 2017
Mohamed, S; McInerney, V; Dunne, A; Hayat, A; Krawczyk, J; Naughton, S; Tarpey, M; Finnerty, A; Duffy, A; Moloney, T; Kavanagh, E; Howard, L; Liew, A; Tubassam, M; Walsh, SR; O’Brien, T (2017) Autologous mesenchymal stem cells as a novel therapy for no-option critical limb ischemia: preliminary results of a phase 1 study Sylvester O’Halloran Meeting 2017 [Details]
(2007) Irish Endocrine Society 32nd Annual Meeting
Liew A, Bowes T, McDermott J, Kealy B, Howard L, O'Regan A, Flynn A, Coleman C, Avalos G, Barry F, Wicox C, O'Brien T. (2007) Endothelial Progenitor Cell disfunction in Diabetes Mellitus: A role of osteopontin Irish Endocrine Society 32nd Annual Meeting Belfast, Northern Ireland, [Details]

Other Journals

  Year Publication
(2017) '• Feasibility of autologous mesenchymal stem cells therapy for patients with no-option critical limb ischemia'
Mohamed, S. ; Howard, L. ; Duffy, A. ; Finnerty, A. ; Holohan, M. ; Doroshenkova, T. ; Mcinerney, V. ; Hayat, A. ; Krawczyk, J. ; Naughton, S. ; Tarpey, M. ; Moloney, T. ; Kavanagh, E. ; Liew, A. ; Tubassam, M. ; Walsh, S. ; O'Brien, T. (2017) '• Feasibility of autologous mesenchymal stem cells therapy for patients with no-option critical limb ischemia' Cytotherapy, The Journal of Cell Therapy, 19 (5) :S186-S187. [DOI] [Details]
(2017) 'Autologous mesenchymal stem cells as a novel therapy for no-option critical limb ischemia: Preliminary results of a phase 1 study'
Mohamed, S. ; Mcinerney, V. ; Dunne, A. ; Hayat, A. ; Krawczyk, J. ; Naughton, S. ; Tarpey, M. ; Finnerty, A. ; Holohan, M. ; Duffy, A. ; Moloney, T. ; Kavanagh, E. ; Burke, P. ; Abdeldaim, Y. ; Moloney, M. Clarke ; Howard, L. ; Liew, A. ; Tubassam, M. ; Walsh, S. ; O'Brien, T. (2017) 'Autologous mesenchymal stem cells as a novel therapy for no-option critical limb ischemia: Preliminary results of a phase 1 study' Cytotherapy, 19 (5) :S198-S198. [DOI] [Details]

Conference Contributions

  Year Publication
Sylvester O’Halloran Meeting 2017,
Mohamed, S; Viknaswaran, N; Howard, L; Tubassam, M; O’Brien, T; Walsh, SR Validation of ERICVA risk ccore as a predictor of one year amputation free survival of patients with critical limb ischemia. [Poster Presentation], Sylvester O’Halloran Meeting 2017, Limerick . [Details]
Autologous mesenchymal stem cells as a novel therapy for no-option critical limb ischemia: preliminary results of a phase 1 study,
Mohamed, S,McInerney, V,Dunne, A,Hayat, A,Krawczyk, J,Naughton, S,Tarpey, M,Finnerty, A,Duffy, A,Moloney, T,Kavanagh, E,Howard, L,Liew, A,Tubassam, M,Walsh, SR,O'Brien, T IRISH JOURNAL OF MEDICAL SCIENCE. [Published Abstract], Autologous mesenchymal stem cells as a novel therapy for no-option critical limb ischemia: preliminary results of a phase 1 study, Sylvester O'Halloran Surgical Symposium Limerick . [Details]
(2017) 25th Sylvester O’Halloran Perioperative Scientific Symposium, 2017,
Mohamed, S; McInerney, V; Dunne, A.; Hayat, A; Krawczyk, J; Naughton, S; Tarpey, M; Finnerty, A; Duffy, A; Moloney, T; Kavanagh, E; Howard, L; Liew, A; Tubassam, M; Walsh S; O’Brien, T. (2017) Autologous mesenchymal stem cells as a novel therapy for no-option critical limb ischemia: preliminary results of a phase 1 study. [Oral Presentation], 25th Sylvester O’Halloran Perioperative Scientific Symposium, 2017, University of Limerick , 02-MAR-17 - 04-MAR-17. [Details]

Abstract

  Year Publication
(2008) Glial-Derived Neurotrophic Factor–Expressing Mesenchymal Stem Cells Survive Transplantation into the Contused Spinal Cord without Differentiating into Neural Cells. Society for Neuroscience, Washington, USA.
Rooney, Gemma E, McMahon, S, Ritter, T, Garcia, Y, Madigan, N, Flugel, A, Nickander, Kim, Dockery, P, O'Brien, T, Howard, L, Windebank, AJ, Barry, F (2008) Glial-Derived Neurotrophic Factor–Expressing Mesenchymal Stem Cells Survive Transplantation into the Contused Spinal Cord without Differentiating into Neural Cells. Society for Neuroscience, Washington, USA. Abstract [Details]
(2007) A Tissue engineering strategies for spinal cord Injury using mesenchymal stem cells. Keystone Tissue Engineering and Developmental Biology conference Utah USA.
Rooney, GE, Moran, C, McMahon, SS, Ritter, T, Maenz, M, Fluegel, A, Dockery, P, O' Brien, T, Howard, L, Windebank, AJ, Barry, FP (2007) A Tissue engineering strategies for spinal cord Injury using mesenchymal stem cells. Keystone Tissue Engineering and Developmental Biology conference Utah USA. Abstract [Details]
(2006) Lentiviral vector transduction efficiency and biosafety profile of aldult mesenchymal stem cells. American Societ of Gene Therapy 2006 Meeting, Baltimore, Maryland, USA.
McGrath, BM, O'Shea, C, Howard, L, Murphy, M, Barry, F, O'Brien, T, Strappe, P (2006) Lentiviral vector transduction efficiency and biosafety profile of aldult mesenchymal stem cells. American Societ of Gene Therapy 2006 Meeting, Baltimore, Maryland, USA. Abstract [Details]

Editorial

  Year Publication
(2020) Derivation of familial iPSC lines from three patients with retinitis pigmentosa carrying an autosomal dominant RPE65 mutation (NUIGi027-A, NUIGi028-A, NUIGi029-A).
Ding, YC;Carvalho, E;Murphy, C;McInerney, V;Krawczyk, J;O'Brien, T;Howard, L;Cai, L;Shen, SB (2020) Derivation of familial iPSC lines from three patients with retinitis pigmentosa carrying an autosomal dominant RPE65 mutation (NUIGi027-A, NUIGi028-A, NUIGi029-A). AMSTERDAM: ELSEVIER Editorial [DOI] [Details]
(2020) Derivation of familial iPSC lines from three patients with retinitis pigmentosa carrying an autosomal dominant RPE65 mutation (NUIGi027-A, NUIGi028-A, NUIGi029-A).
Ding, YC,Carvalho, E,Murphy, C,McInerney, V,Krawczyk, J,O'Brien, T,Howard, L,Cai, L,Shen, SB (2020) Derivation of familial iPSC lines from three patients with retinitis pigmentosa carrying an autosomal dominant RPE65 mutation (NUIGi027-A, NUIGi028-A, NUIGi029-A). Editorial [DOI] [Details]
(2019) Derivation of familial iPSC lines from three ASD patients carrying NRXN1 alpha(+/-) and two controls (NUIGi022-A, NUIGi022-B; NUIGi023-A, NUIGi023-B; NUIGi025-A, NUIGi025-B; NUIGi024-A, NUIGi024-B; NUIGi026-A, NUIGi026-B).
Ding, YC;de la Cruz, BM;Xia, YW;Liu, M;Lu, Y;McInerney, V;Krawczyk, J;Lynch, SA;Howard, L;O'Brien, T;Gallagher, L;Shen, SB (2019) Derivation of familial iPSC lines from three ASD patients carrying NRXN1 alpha(+/-) and two controls (NUIGi022-A, NUIGi022-B; NUIGi023-A, NUIGi023-B; NUIGi025-A, NUIGi025-B; NUIGi024-A, NUIGi024-B; NUIGi026-A, NUIGi026-B). AMSTERDAM: ELSEVIER Editorial [DOI] [Details]
(2010) Investigating the Ability of Anti-Oxidant Gene Expression in Mesenchymal Stem Cells to Promote Cell Protection and Recovery in an in vitro Model of Age-Related Macular Degeneration.
Lynch, AP,McGinley, L,Sheridan, C,Coleman, C,Howard, L,Kent, D,Barry, F (2010) Investigating the Ability of Anti-Oxidant Gene Expression in Mesenchymal Stem Cells to Promote Cell Protection and Recovery in an in vitro Model of Age-Related Macular Degeneration. Editorial [Details]

Meeting

  Year Publication
(2010) MESENCHYMAL STEM CELLS FROM THE GREEN FLUORESCENT PROTEIN TRANSGENIC RAT ARE HYPOIMMUNOGENIC FOLLOWING TRANSPLANTATION TO THE INTACT ADULT RAT STRIATUM.
Moloney, TC,Dockery, P,Barry, FP,Windebank, AJ,Howard, L,Dowd, E (2010) MESENCHYMAL STEM CELLS FROM THE GREEN FLUORESCENT PROTEIN TRANSGENIC RAT ARE HYPOIMMUNOGENIC FOLLOWING TRANSPLANTATION TO THE INTACT ADULT RAT STRIATUM. Meeting [Details]
(2007) An alternative strategy to reduce instent restenosis and prevent late stent thrombosis through enhanced endothelial regeneration using eNOS gene-eluting stents.
Sharif, F,Hynes, SO,Cooney, R,Howard, L,Mcmahon, J,Daly, K,Crowley, J,Barry, F,O'brien, T (2007) An alternative strategy to reduce instent restenosis and prevent late stent thrombosis through enhanced endothelial regeneration using eNOS gene-eluting stents. Meeting [Details]

Reviews

  Year Publication
(2019) Long QT Syndrome: Genetics and Future Perspective.
Wallace, E;Howard, L;Liu, M;O'Brien, T;Ward, D;Shen, SB;Prendiville, T (2019) Long QT Syndrome: Genetics and Future Perspective. NEW YORK: SPRINGER Reviews [DOI] [Details]

Committees

  Committee Function From / To
School of Medicine Workload Allocation Model Committee Member 01-SEP-22 /
Cell and Gene Therapy Forum Education and Training Working Group Member 01-SEP-22 /
College of Medicine Workload Allocation Model Committee Member 01-SEP-22 /
College of Medicine Board of Studies Representative for School of Medicine Taught Postgraduate courses 01-FEB-16 /
School of Medicine School Board Representative for Taught Postgraduate Programs 01-JAN-16 / 01-DEC-18
School Post Graduate Taught Committee Chair 01-JAN-16 / 30-NOV-18
School of Medicine Executive Committee Taught postgraduate course representative 01-FEB-16 / 01-DEC-18
School of Natural Sciences Postgraduate Committee Representative for the NCBES 01-SEP-14 / 01-JAN-19
School of Medicine Postgraduate strategy Committee M.Sc in Regenerative Medicine Coordinator 01-JAN-08 /

Community Engagement

  Title Type From / To
Outreach Reellife Science 01-SEP-15 /

Other Activities

  Description

External Examiner for Postgraduate certificate/postgraduate diploma in Stem Cell Biology University of Ulster, Coleraine, UK. 2014-2019

2023-2026: External Examiner for Postgraduate Diploma and Masters in Advanced Cell and Gene Therapy at UCC/NIBRT Ireland.

External Examiner for M.Sc in Stem Cells and Regenerative Medicine, University of Aston, Birmingham UK. 2014-2019

Teaching Interests

I am the course director for the taught M.Sc in Regenerative medicine at NUI Galway.
I am involved with teaching Ph.D. students, M.Sc students as well as undergraduate science and medicine students. My topics of interest are stem cells, regenerative medicine, gene therapy, molecular biology and biomedical research techniques. I am also interested in the process of moving a research finding from the laboratory into the clinic. I am a great believer in problem based learning and in hands on research training.

Modules Taught

  Term/Year Module Title Module Code Subject / Desc
2007-2019 Semester I Molecular & Regenerative Medicine BES510 Regenerative Medicine, Stem Cells and Gene Therapy
2007-2024 Independent Study Module REM506 Literature Review
2013 Semester I Stem Cell Biology BG418
2018-present Mesenchymal Stromal Cell Therapy MD1526
2007-present full calendar year M.Sc in Regenerative Medicine 1MSR1 Stem cells, gene therapy, tissue engineering and their translation to the clinic.
2011-present Semester II Stem Cell & Gene Therapy MD507 Stem cells
2018-present Semester II Experimental Toxicology PM5109 Tutorials and lab-based training in analysis of transcripts.
2018-present Semester II Experimental Neuropharmacology PM5103 Tutorials and lab-based training in analysis of transcripts.
2011-2013 Stem Cell & Gene Therapy MD810, MD802, MD812 Modules for National Graduate Education Programs
2024-present Stem Cells and Regenerative Medicine MD1542
2024-present Gene Therapy SI5100
2010-2018 Semester II Molecular Medicine BES554 Stem Cell Biology and Gene Therapy
2006-2014 Semester II Special Study Module in Regenerative Medicine (1st year medical students) MD129 Regenerative medicine, Stem cells, Gene Therapy
2007-present Semesters I and II Advanced Research Techniques REM503 Hands on training in stem cell culture, stem cell differentiation assays, RNA isolation, quantitative RT PCR, protein gel electrophoresis, flow cytometry and molecular biology.
Biotechnology Stem cells, stem cells and disease, creating pluripotent stem cells from somatic cells
2007-present Summer Term Research Project REM505 A key element of the taught M.Sc. is an individual research project. Over 4-5 months you will get significant research experience including presenting your research findings as a poster, as an oral presentation and also as a written thesis.
2007- 2024 Semester I and II Regenerative Medicine REM504 Stem cells, gene therapy, tissue engineering, recombinant proteins and scaffolds
2007-present Semester II Translational Medicine REM502 What steps are required in order to take a research finding and use it to develop a therpay (or diagnostic)? This course covers the steps involved and the ethics to be considered.

Internal Collaborators

  Name Description of Collaboration
Dr Cynthia Coleman
Dr Aideen Ryan
Dr Roisin Dwyer
Dr Meadhbh Brennan
Prof Tim O'Brien
Professor Sanbing Shen
Dr Kasia Whysall
Dr Michelle Kilcoyne

External Collaborators

  Name Organisation / Institute Country Description of Collaboration
Professor Anthony Windebank Mayo Clinic U.S.A.
Dr Nicolas Madigan Mayo Clinic U.S.A.